Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sanara MedTech (SMTI) Gains from Sales and Divestitures (2020 - 2025)

Sanara MedTech (SMTI) has disclosed Gains from Sales and Divestitures for 6 consecutive years, with $123591.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Gains from Sales and Divestitures rose 46.42% year-over-year to $123591.0, compared with a TTM value of $123591.0 through Sep 2025, up 46.42%, and an annual FY2024 reading of $105875.0, down 23.12% over the prior year.
  • Gains from Sales and Divestitures was $123591.0 for Q3 2025 at Sanara MedTech, up from $113252.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $154307.0 in Q4 2022 and bottomed at $51656.0 in Q1 2024.
  • Average Gains from Sales and Divestitures over 5 years is $101066.9, with a median of $109563.5 recorded in 2024.
  • The sharpest move saw Gains from Sales and Divestitures soared 154.81% in 2022, then crashed 38.0% in 2023.
  • Year by year, Gains from Sales and Divestitures stood at $68661.0 in 2021, then surged by 124.74% to $154307.0 in 2022, then fell by 10.75% to $137720.0 in 2023, then dropped by 23.12% to $105875.0 in 2024, then rose by 16.73% to $123591.0 in 2025.
  • Business Quant data shows Gains from Sales and Divestitures for SMTI at $123591.0 in Q3 2025, $113252.0 in Q2 2025, and $62151.0 in Q1 2025.